

First Named Inventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS



First Named Inventor: John M. Flack

Application Seriai No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS




1

Title: COMPUTER-IMPLEMENTED METHOD AND SYSTEM FOR MANAGING FATIENT HEALTHCARE AND EVALUATING PATIENT KIDNEY FUNCTION

First Named Inventor: John M. Flack


Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS





First Named Inventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS




First Named Inventor: John M. Flack
Application Serial No.: 10/036,202 / Arty, Docket No.: MTS 9102 PUS

|--|


First Named Inventor: John M. Flack

Application Geria: No.: 10/036,202 / Atty. Docket No.: MTS 6102 PUS



First Named Irventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS




168-


Title: COMPUTER-IMPLEMENTED METHOD AND SYSTEM FOR MANAGING PATIENT HEALTHCARE AND EVALUATING PATIENT KIDNEY FUNCTION

First Named Inventor: John M. Flack

Apparention Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS


8/27






First Named Inventor: John M. Flack

Application Seriai No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS




First Named Inventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS



First Named Inventor: John M. Flack

Application Seria: No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS



First Named Inventor: John M. Flack
Application Serial No.: 10/036,202 / Aity. Docket No.: MTS 0102 PUS

	Patient: Doe, John	Close
	SSN: 123-12-1234	Open Lab Visit for this Crder
	Date of Visit: 01/03/1999	214
	Cirrant Jah 1 F. 1	Lab Orders
	1 Urine Albumin	umin
	Crea (Serum)	(mn)
		24hr Blood Pressure Monitor
	Giock slieet:	
·	Carvel Order	Order Checked Labs
	CBC	
	Cholesterol	
	OK	
	CPK	
7016	Crea (Serum)	
·	CT scan-Head	
	Dietary: 1800 ADA Diet	
-	Dietary: 2 gram sodium diet	liet
	Dietary: 2000 ADA Diet	
	Dietary: 2200 ADA Diet	
	G. ataalacta tow for low abalactara	acta al diat
J		
	*	
	206	Str. 13

First Named Inventor: John M. Flack

Application Sana, No.: 10/036,202 / Atty. Docket No.: MTS 6102 PUS

13/27





Fig. 14

216


First Named Inventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS



First Named Inventor: Jehn M. Flack

Application Grain No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS



First Named Inventor: John M. Flack
Application Seria, No.: 10/036,202 / Atty. Docket No.: MTS 9102 PUS

	Close	is accurate!						cord, field changes int record.	American de la companya de la compan
		Always verify that the information below is accurate	Age: 75 (yr)	69.0	ht: [172.0] (lb)	ne: 1.6 (mg/dl)	EGFR 39.3	Note: Although the data is imported from the patient record, field changes made on this form are NOT stored in the patient record.	10
	234	verify that the in	Age:	Get Fieight:	Weight:	Saruin Greatinine.	EG	he data is imported on this form are NO	S
EGFR Calculator	Patient: Doe, John SSN: 1233-12-1234	Always		236*				Note: Although t	

First Named Inventor: John M. Flack

Application Serv. No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS

17/27





Fig. 18

38

First Named Inventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS



First Named Inventor: John M. Flack
Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS

Impression / Treatment Plan	
Patient: Doe, John	Lab Orders
Visit Date: 1/3/99	Crea (Serum) Order lab lests From Sheet Other Blood Descure Monitor
	9.2 -
Impression Treatment Plan	
Impression:	HELICAL TOWNS AND THE CASE AND
Renal artery duplex scan, stress echocardiogram, start Norvasc 2.5 mg Q day, EKG, and review his labs and serum TSH. Will continue treatment with Viagra for his impotence if he does not have easily induced coronary ischemia or stress echocariography.	g Q day, EKG, and review his labs and serum TSH. Will continue aced coronary ischemia or stress echocariography.
Other Visit Impression(c), for Patient Preforatted Statements (A)	Preforatted Statements (A) Preforatted Statements (B) Preforatted Statements (C)
Return to clinic in 2-3 weeks.	
Return to clinic in 3 months.	
Return to clinic in 4-6 months.	
Return to clinic in 4-6 weeks.	
The patient is being referred to the dietician for a 2 gram sodium, low-fat, low-cholesterol diet.	w-fat, low-cholesterol diet.
Will check lutes BUN and creatinine on return.	

Title: COMPUTER-IMPLEMENTED METHOD AND SYSTEM FOR MANAGING PATIENT HEALTHCARE AND EVALUATING PATIENT KIDNEY FUNCTION

First Named Inventor: John M. Flack

Application Seria, No.: 10/036,202 / Atty. Docket No : MTS 3102 PUS


20/27

It is prudent to wait ~4 to 6 weeks prior to titrating antihypertensive medications to maximize BP lowering and to minimize drug-For patients with ED: 1) if hypertensive, avoid thiazide diuretics, beta blockers (particularly older ones), and central adrenergic Preventive: Patients 50 years and older should have colonoscopy if primary relative has colorectal cancer and every 5 years Meets criteria for HTN based on diabetes, CHF, CRI, and SBP at least 130 or DBP at least 85 or on antihypertensive meds. Close In esthmatics with ASA sensitivity, non-acetylated calicylates (Trilisate, Disalcid, etc.) are less likely to cause severse tronchospasm & anaphylactoid reactions. However, these reactions may occur with any NSAID Due to history of sulfa drug allergy, avoid thiazide diuretics or use them with caution Preventive: Patients 40 years and older should have stool checked for occult blood (c) Calculated Statements inhibitors. Favor use of alpha blockers. 2) Consider sildenafil (Viagra) Due to history of CHF, avoid use of thiazolidiediones and metformin. Meets criteria for impaired fasting glucose based on lab results. after 2 negative exams. Diagnöstic Subform related side effects.

Sig. 21

First Named Inventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS



First Named Inventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS

22/27




Fig. 23

First Named Inventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 3102 PUS

23/27

Wayne State University	Re: DOE, JOE A.	مح(ا	. Print	j. Close
Internal Medicine	Med Rec#: 123-12-1234		· · · · · · ·	
· · · · · · · · · · · · · · · · ·				
November 15, 2000		. •		
REFERRING PHYSICIAN INFORMATION				•
				• • • • •
First Name: John	Address1: 4201 St. Antoine, Suit			
MI: A Last Name. Salameier	Onivorsity Trouter Cont	er		
Degrees: MD	City: Detroit State: MI	. النب		
Phone: (313) 745-8000	Zip: 48201	• .		
Fax: (313) 745-5545	Comments:	-		·
Email: isalameier@intmed.wayne.ed				
Journal of Children				• . • •
Dear Dr. Salameier,				
Thankyou very modernor your and hone	ral of John Oce 20B.3/5/1925, for evaluation	3771.1007,34	is a copy of my c	mino.ijoto.
IMPRESSION: Gentleman with ESRD ca peritoneal dialva	sis with HTN of unknown duration. His sympt	of dyspn	ea on moderate ex	xertion
Gentleman with EGRD on peritoneal dialy point to the need to screen for systolic an combined hypertensive an ischemic care claudination symptoms. He is currently in prostate cancer. Atherosclerosis also may	sis with HTN of unknown duration. His sympted diastotic heart dysfunction and, if systolic difference, it is suspect that he has some perignotent, a problem likely secondary to his hypy be playing a role in his impotence. His cerebessness also may relate to primary pulmonary	ysfunction is ; bheral arterial ertension and ellar dysmetria	oresent, to consid disease and mild radiation treatme	ler ent for
Gentleman with ESRD on peritoneal dialyy point to the need to screen for systolic an combined hypertensive an iscaemic car claudination symptoms. He is currently in prostate cancer. Atherosclerosis also may remote ETOH intake. Some of his breathle	d diastoile heart dysfunction and, if systolic d diomyopathy. I suspect that he has some perip apotent, a problem likely secondary to his hyp y be playing a role in his impotence. His cerebo	ysfunction is ; bheral arterial ertension and ellar dysmetria	oresent, to consid disease and mild radiation treatme a is possibly linke	ent for d to
Gentleman with EGRD on peritoneal dialy point to the need to screen for systolic an combined hypertensive an 'ischemic care claudination symptoms. He is currently in prostate cancer. Atherosclerosis also may remote ETOH intake. Some of his breathle PROBLEMS:	d diastoile heart dysfunction and, if systolic diomyopathy. I suspect that he has some perigopotent, a problem likely secondary to his hypy be playing a role in his impotence. His cerebessness also may relate to primary pulmonary	ysfunction is ; bheral arterial ertension and ellar dysmetria	oresent, to consid disease and mild radiation treatme	ent for d to
Gentleman with ESRD on peritoneal dialyy point to the need to screen for systolic an combined hypertensive an iscaemic car claudination symptoms. He is currently in prostate cancer. Atherosclerosis also may remote ETOH intake. Some of his breathle	d diastoile heart dysfunction and, if systolic diomyopathy, i suspect that he has some perigopotent, a problem likely secondary to his hypy be playing a role in his impotence. His cerebessness also may relate to primary pulmonary	ysfunction is oberal arterial ertension and ellar dysmetrial disease.	oresent, to consid disease and mild radiation treatme a is possibly linke	ent for d to
Gentleman with E3RD on peritoneal dialy point to the need to screen for systolic an combined hypertensive an 'iscaemic care claudination symptoms. He is currently in prostate cancer. Atherosclerosis also may remote ETCH intake. Some of his breathle PROBLEMS: Problem: Hypertension LVH Pulmonary hypertension	d diastoile heart dysfunction and, if systolic diomyopathy, i suspect that he has some perigopotent, a problem likely secondary to his hypy be playing a role in his impotence. His cerebessness also may relate to primary pulmonary	ysfunction is oberal arterial ertension and ellar dysmetrial disease.	oresent, to consid disease and mild radiation treatme a is possibly linke	ent for d to
Centleman with E3RD on peritoneal dialyy point to the need to screen for systolic an combined hypertensive an iscaemic care claudination symptoms. He is currently in prostate cancer. Atherosclerosis also may remote ETOH intake. Some of his breathle PROBLEMS: Problem: Hypertension LVH Pulmonary hypertension End Stage Renal disease (ESRD)	d diastoiic heart dysfunction and, if systolic diomyopathy. I suspact that he has some perignotent, a problem likely secondary to his hyp be playing a role in his impotence. His cerebessness also may relate to primary pulmonary	ysfunction is oberal arterial ertension and ellar dysmetrial disease.	oresent, to consid disease and mild radiation treatme a is possibly linke	ent for d to
Gentleman with EGRD on peritoneal dialy point to the need to screen for systolic an combined hypertensive an ischemic care claudination symptoms. He is currently in prostate cancer. Atherosclerosis also may remote ETCH intake. Some of his breathle PROBLEMS: Problem: Problem:	d diastoile heart dysfunction and, if systolic diomyopathy, i suspect that he has some perigopotent, a problem likely secondary to his hypy be playing a role in his impotence. His cerebessness also may relate to primary pulmonary	ysfunction is oberal arterial ertension and ellar dysmetrial disease.	oresent, to consid disease and mild radiation treatme a is possibly linke	ent for d to
Centleman with E3RD on peritoneal dialyy point to the need to screen for systolic an combined hypertensive an iscaemic care claudination symptoms. He is currently in prostate cancer. Atherosclerosis also may remote ETOH intake. Some of his breathle PROBLEMS: Problem: Hypertension LVH Pulmonary hypertension End Stage Renal disease (ESRD)	d diastoiic heart dysfunction and, if systolic diomyopathy. I suspact that he has some perignotent, a problem likely secondary to his hyp be playing a role in his impotence. His cerebessness also may relate to primary pulmonary	ysfunction is oberal arterial ertension and ellar dysmetrial disease.	oresent, to consid disease and mild radiation treatme a is possibly linke	ent for d to
Gentleman with EGRD on peritoneal dialy point to the need to screen for systolic an combined hypertensive an ischemic care claudination symptoms. He is currently in prostate cancer. Atherosclerosis also may remote ETCH intake. Some of his breathle PROBLEMS: Problem: Problem:	d diastoiic heart dysfunction and, if systolic diomyopathy. I suspact that he has some perignotent, a problem likely secondary to his hyp be playing a role in his impotence. His cerebessness also may relate to primary pulmonary	ysfunction is pheral arterial ertension and allar dysmetria disease.	oresent, to consid disease and mild radiation treatme a is possibly linke	ed

260 -

Fig. 24

First Named Inventor: John M. Flack


Application Serial No.: 10/036,232 / Atty. Decket No.: MTS 0102 PUS

			1	
Append Selected Physician	M Smith MD MPH) MI Last Degrees (MD, MPH) Address 2: Suite 4A (313) 555-8823 MD Fax	you for . I teve incuded fry Visit notes.	neal dialysis with HTN of unknown duration. His symptoms of dyspnea on moderate exertion point c and diastolic heart dysfunction and, if systolic dysfunction is present, to consider combined iomyopathy. I suspect that he has some peripheral cierial disease and mild claudication symptoms.	Sin. 25
November 14, 2000 Physician Directory:	Fredricl First 3 3rd Ave.	;	MPRESSIGN: Gentleman with ESRD on perito to the need to screen for systol hypertensive and ischemic card	
		edrick st	edrick M Smith MD Sulte 4A MD MPH) 1 Ave. Address 2: Suite 4A MD MPH) ate Zip Fax	edrick M Smith MD Smith

First Named Inventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS

25/27




Sig. 2

-897

First Named Inventor: John M. Flack

Application Serial No.: 10/036,30% / Atty. Docket No.: MTS 0102 PUS



First Named Inventor: John M. Flack

Application Serial No.: 10/036,202 / Atty. Docket No.: MTS 0102 PUS

27/2.7

	Age (years) Thru Report Variables Wattaining Goal BP Average Number of Follow-Up Visits Average Number of Follow-Up Visits Average Number of Follow-Up Visits Average Number of Follow-Up Average Number of Follow-Up Anti-Hypertensive Medications Average Pretragtme.t. 39:1 Pressure Average Pretragtmententententententententententententente
Clinical Administrative Report	Physician Provider O All O Physician B O Prysician C Time Feriod Time Feriod Time Feriod Thru

Fig. 28

.9/2